Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Controlled and Double-blinded Study of the Effect of a Specific Aquaporin-1 Inhibitor, Bacopaside II (KeenMind®), on Vascular Oxidative Stress in Healthy Volunteers

NCT06059131 is registered in ClinicalTrials.gov with Cliniques universitaires Saint-Luc- Université Catholique de Louvain as lead sponsor.

NCT NCT06059131
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06059131 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Controlled and Double-blinded Study of the Effect of a Specific Aquaporin-1 Inhibitor, Bacopaside II (KeenMind®), on Vascular Oxidative Stress in Healthy Volunteers
Lead sponsor
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase
Not applicable
Overall status
Completed
Start date
January 3, 2023
Completion date
October 31, 2023
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

aqp1, aquaporin 1, bacopa monnieri, bacopaside ii, cardiovascular diseases, endothelial dysfunction, oxidative stress